FDA approves Brisdelle(TM)(paroxetine) capsules, the first and only nonhormonal therapy for the treatment of moderate to severe vasomotor symptoms associated with menopause, commonly referred to as hot flashes and night sweats.  (PRNewsFoto/Noven Pharmaceuticals, Inc.)
{"Image Orientation": "0", "Image XResolution": "0", "Image YResolution": "0", "Image ResolutionUnit": "Pixels/Inch", "Image Software": "Adobe Photoshop CS3 Windows", "Image DateTime": "2013:06:28 16:34:00", "Image ExifOffset": "164", "Thumbnail Compression": "JPEG (old-style)", "Thumbnail XResolution": "0", "Thumbnail YResolution": "0", "Thumbnail ResolutionUnit": "Pixels/Inch", "Thumbnail JPEGInterchangeFormat": "302", "Thumbnail JPEGInterchangeFormatLength": "2631", "EXIF ColorSpace": "sRGB", "EXIF ExifImageWidth": "2700", "EXIF ExifImageLength": "1800"}